--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-280679" form_type: "8-K" ticker: null cik: "0001069308" company_name: "Acer Therapeutics Inc." filed_at: "2023-11-20T23:59:59+00:00" generated_at: "2026-06-07T23:10:25.211486+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # Acer Therapeutics acquired by Zevra in all-stock merger; shareholders receive 0.1210 ZVRA shares + CVR ## Summary - Merger completed on Nov 17, 2023; Acer becomes wholly-owned subsidiary of Zevra. - Each ACER share converted into 0.1210 Zevra shares and one contingent value right (CVR). - All Acer directors and executive officers (CEO Chris Schelling, CFO Harry Palmin) resigned; R. LaDuane Clifton and Joshua Schafer appointed directors. - Acer's common stock now trades on OTC Pink; Nasdaq delisting expected via Form 25-NSE on Nov 20. ## SEC filing metadata - accession: 0001193125-23-280679 - form_type: 8-K - cik: 0001069308 - company_name: Acer Therapeutics Inc. - filed_at: 2023-11-20T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 2.01, 3.03, 3.01, 5.01, 5.02, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/d608859d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-280679 - JSON: https://secwatch.observer/filing/0001193125-23-280679.json - Plain text: https://secwatch.observer/filing/0001193125-23-280679.txt ## Key facts - Executive change Harry S. Palmin departed as Chief Financial Officer at Acer Therapeutics Inc.. - Action: ceased - Role: Chief Financial Officer source text: On November 17, 2023, each of Chris Schelling, Acer’s President and Chief Executive Officer, and Harry S. Palmin, Acer’s Chief Financial Officer, ceased to be an executive officer of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change John M. Dunn resigned as Director at Acer Therapeutics Inc.. - Action: resigned - Role: Director source text: Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Jason Amello resigned as Director at Acer Therapeutics Inc.. - Action: resigned - Role: Director source text: Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Stephen J. Aselage resigned as Director at Acer Therapeutics Inc.. - Action: resigned - Role: Director source text: Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Chris Schelling departed as President and Chief Executive Officer at Acer Therapeutics Inc.. - Action: ceased - Role: President and Chief Executive Officer source text: On November 17, 2023, each of Chris Schelling, Acer’s President and Chief Executive Officer, and Harry S. Palmin, Acer’s Chief Financial Officer, ceased to be an executive officer of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Michelle Griffin resigned as Director at Acer Therapeutics Inc.. - Action: resigned - Role: Director source text: Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Joshua Schafer was appointed as Director at Acer Therapeutics Inc.. - Action: appointed - Role: Director source text: On November 17, 2023, R. LaDuane Clifton and Joshua Schafer became the directors of the surviving corporation. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change R. LaDuane Clifton was appointed as Director at Acer Therapeutics Inc.. - Action: appointed - Role: Director source text: On November 17, 2023, R. LaDuane Clifton and Joshua Schafer became the directors of the surviving corporation. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Executive change Chris Schelling resigned as Director at Acer Therapeutics Inc.. - Action: resigned - Role: Director source text: Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Governance Changes Acer Therapeutics Inc.: Bylaws amended and restated to match Merger Sub's bylaws. - Change: bylaw amendment source text: Acer’s bylaws were amended and restated to read in their entirety as the bylaws of Merger Sub in effect immediately prior to the Effective Time evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - Governance Changes Acer Therapeutics Inc.: Certificate of incorporation amended and restated to match Merger Sub's certificate. - Change: charter amendment source text: Acer’s certificate of incorporation was amended and restated to read in its entirety (other than the name of Acer) as the certificate of incorporation of Merger Sub in effect immediately prior to the Effective Time evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm - M&A Transactions Acer Therapeutics Inc. underwent a change of control involving Zevra Therapeutics, Inc. (closed 2023-11-17). - Action: change of control - Counterparty: Zevra Therapeutics, Inc. - Closing: 2023-11-17 source text: On November 17, 2023 (the “ Closing Date ”), the Merger was completed pursuant to the terms and conditions of the Merger Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.